You are here

Press Release Archive

- CP-690,550, Pfizer’s Oral JAK Inhibitor, Demonstrates Response Both Alone And In Combination With Methotrexate At 24 Weeks In Patients With Active Rheumatoid Arthritis

(BUSINESS WIRE) Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week at the 2009 ACR/ARHP Annual Scientific Meeting in

- Pfizer Commences Consent Solicitation for Amendments to Wyeth Indenture

(BUSINESS WIRE) Pfizer today announced that it has commenced a consent solicitation to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary: Aggregate Debt Security

- Pfizer And Wyeth Become One: Working Together For A Healthier World™

(BUSINESS WIRE) Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline,

- Pfizer Completes Acquisition Of Wyeth

(BUSINESS WIRE) fizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a

- Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau For Wyeth Acquisition

(BUSINESS WIRE) Pfizer Inc (NYSE:PFE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition. With the receipt of these clearances, Pfizer has now satisfied the

- Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend®

(BUSINESS WIRE) Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer’s Vfend products for intravenous use or oral suspension. Pursuant to the agreement, Mylan will have the right to market voriconazole tablets in the

- FDA Advisory Committee Recommends Approval of Pfizer’s Selzentry for Use in Patients Starting HIV Therapy for the First Time

(BUSINESS WIRE)  Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy. “Pfizer is pleased that the Committee has recognized the effectiveness and safety profile of

- Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain animal health assets in Australia. “We are pleased to have achieved another significant milestone this week with the ACCC’s approval of the pending acquisition,” said

- Pfizer Receives Approval from China’s Ministry of Commerce for Pending Wyeth Acquisition

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that China’s Ministry of Commerce has approved the company’s pending acquisition of Wyeth. The Ministry’s decision includes Pfizer’s commitment to divest certain animal health assets in China. “We are pleased to have achieved another significant milestone with the Ministry’s approval of the pending transaction,” said Jeff Kindler,

- Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors

(BUSINESS WIRE)--Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of Pfizer’s pending acquisition of Wyeth in accordance with the terms of the merger agreement. Dr. Fergusson is President Emeritus and professor of art at Vassar

- Pfizer and Eisai Continue Aricept Collaboration

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the

- Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

(BUSINESS WIRE)--Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy. Updated data from an expansion cohort of

- New Survey of People with Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated

(BUSINESS WIRE)--In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition’s impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half

- Pfizer Again Named To Working Mother 100 Best Companies List

(BUSINESS WIRE)--Pfizer Inc has been named among the 2009 Working Mother 100 Best Companies for its steadfast commitment to family-friendly benefits. Pfizer and the other winning companies are pioneering programs that support families, with 100 percent offering flextime, on-site lactation and telecommuting; and 98 percent offering job-sharing and wellness programs—numbers that dwarf those seen nationwide. In addition, financial programs

- Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

(BUSINESS WIRE)--Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events (HR=0.82; 95% CI: 0.73-0.92; P=0.0009), compared to women who continued on tamoxifen for a full five years of treatment.1 In

- Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge,

- Pfizer Commended For Leadership In Addressing Climate Change For Third Consecutive Year

(BUSINESS WIRE)--Pfizer Inc has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. CDP named Pfizer to its Climate Disclosure Leadership Index, which highlights the company’s climate change disclosure practices. This is the third consecutive year that Pfizer has been recognized by CDP. “As a health care company, Pfizer is very aware of the potential impact of climate

- Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents

(BUSINESS WIRE)--Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell

- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, and Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009 at 8:35 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at

- Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices

(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.